Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclosporin H is a non-immunosuppressive cyclic undecapeptide and a diastereomer of the well-known immunosuppressant Cyclosporin A. Unlike Cyclosporin A, which binds to cyclophilin to inhibit calcineurin, Cyclosporin H lacks significant calcineurin-inhibiting activity. Instead, it acts as a potent and selective antagonist of the Formyl Peptide Receptor 1 (FPR1), a G protein-coupled receptor primarily expressed on neutrophils and macrophages. FPR1 plays a critical role in the innate immune response by sensing N-formyl peptides derived from bacteria or damaged mitochondria. By blocking FPR1, Cyclosporin H inhibits leukocyte chemotaxis and the production of reactive oxygen species. Recent research has demonstrated its potential protective effects in sepsis-associated acute kidney injury (SA-AKI) by modulating FPR1 signaling and inhibiting pyroptosis, making it a valuable pharmacological tool for studying FPR1-mediated inflammatory processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclosporin H.